Evidence map›Paper›PMID 38931884›Full record

ReviewPharmaceutics2024

Therapeutic Applications of Nanoformulated Resveratrol and Quercetin Phytochemicals in Colorectal Cancer-An Updated Review.

Dhanalekshmi Unnikrishnan Meenakshi, Gurpreet Kaur Narde, Alka Ahuja, Khalid Al Balushi, Arul Prakash Francis, Shah Alam Khan

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Foods (Basel, Switzerland) · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Molecular Mechanisms of Phytochemicals from Chaga Mushroom (International journal of molecular sciences · 2025
    Article
  11. Review
  12. Review
  13. Article
  14. Resveratrol and pancreatic cancers: Questions and future perspectives.World journal of gastrointestinal oncology · 2025
    Article
  15. TheFrontiers in nutrition · 2025
    Article
  16. Quercetin: A Natural Ally in Combating Breast Cancer.International journal of nanomedicine · 2025
    Review
  17. Observational
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dhanalekshmi Unnikrishnan MeenakshiCollege of Pharmacy, National University of Science and Technology, Muscat PC 130, Oman.ORCID 0000-0002-2689-4079
Gurpreet Kaur NardeCollege of Pharmacy, National University of Science and Technology, Muscat PC 130, Oman.ORCID 0000-0001-5182-4622
Alka AhujaCollege of Pharmacy, National University of Science and Technology, Muscat PC 130, Oman.
Khalid Al BalushiCollege of Pharmacy, National University of Science and Technology, Muscat PC 130, Oman.
Arul Prakash FrancisCentre of Molecular Medicine and Diagnostics (COMMAND), Saveetha Dental College and Hospitals, Saveetha Institute of Medical & Technical Sciences, Saveetha University, Chennai 600077, India.ORCID 0000-0003-1357-6466
Shah Alam KhanCollege of Pharmacy, National University of Science and Technology, Muscat PC 130, Oman.ORCID 0000-0002-0729-3403

Funding

Ministry of Higher Education, Research & Innovation (MoHERI), Oman BFP/RGP/HSS/22/220
6 · The paper itself

Abstract

Natural compounds such as polyphenols play several positive roles in maintaining the oxidative and inflammatory capacity of cells, which leads to their potential use as anticancer therapeutics. There is promising evidence for the in vitro and in vivo anticancer activity of many polyphenols, including resveratrol and quercetin, specifically in the treatment of colorectal cancer (CRC). There is a clear association between resveratrol and quercetin in interfering with the mechanistic pathways involved in CRC, such as Wnt, P13K/AKT, caspase-3, MAPK, NF-κB, etc. These molecular pathways establish the role of resveratrol and quercetin in controlling cancer cell growth, inducing apoptosis, and inhibiting metastasis. The major bottleneck in the progression of the use of resveratrol and quercetin as anticancer therapeutics is their reduced bioavailability in vivo because of their rapid metabolism in humans. Recent advancements in various nanotechnological formulations are promising for overcoming these bioavailability issues. Various nanoformulations of resveratrol and quercetin have shown an optimistic impact on reducing the solubility and improving the stability of resveratrol and quercetin in vivo. A combinatorial approach using nanoformulations of resveratrol with quercetin could potentially increase the impact of resveratrol in controlling CRC cell proliferation. This review discusses the mechanism of resveratrol and quercetin, the two bioactive polyphenolics, in colon cancer, with an emphasis on various types of nanoformulations of the two molecules targeting colon cancer. It also explores the synergistic effect of combining resveratrol and quercetin in various nanoformulations, targeting colon cancer. This research delves into the enhanced pharmacokinetics and potential chemotherapeutic benefits of these bioactive polyphenolics when used together in innovative ways.

Indexed as

AKTcolon cancerMAPKnanoformulationsNF-κBpolyphenolsquercetinresveratrol

Identifiers

PMID38931884
PMCPMC11206904

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.